CJC-1295 and Ipamorelin: A GHRH-Plus-Ghrelin-Mimetic Combination for Pulsatile GH Release

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, compound, or facilitate access to CJC-1295 or ipamorelin. As of April 2026, both compounds appear on the FDA 503A Category 2 bulk substances list and cannot be legally compounded under Section 503A pending further FDA review. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Most people understand that growth hormone declines with age. Fewer understand that the architecture of how growth hormone is released matters as much as the total amount. The body does not release growth hormone continuously; it releases it in discrete, high-amplitude pulses, and both the timing and the magnitude of those pulses depend on coordinated signaling from two distinct receptor pathways. CJC-1295 and ipamorelin each target one of those pathways. The rationale for using them together is not convenience — it is mechanistic.

Here is how these two peptides work individually, why researchers have studied their combined use, what the published evidence actually supports, and where both compounds stand from a regulatory perspective as of April 2026.

Key Takeaways

• Regulatory Status: As of April 2026, both CJC-1295 and ipamorelin are on the FDA 503A Category 2 bulk substances list. Category 2 designation means they cannot be legally compounded under Section 503A pending further FDA review. Neither compound is FDA-approved for any indication. Superpower Health does not offer either compound.
• Research Stage: Individual component pharmacology established in human trials; no published human RCTs of the specific combination exist as of April 2026.
• Availability: Not available through Superpower. Current regulatory status prohibits 503A compounding of these substances. Access through any channel should involve consultation with a qualified healthcare and regulatory professional.
• Prescribing information: PubChem monograph — ipamorelin (CID 20515892); PubChem monograph — CJC-1295 (CID 56841945)
• How they work: CJC-1295 activates GHRH receptors on the anterior pituitary, extending GH pulse amplitude; ipamorelin activates ghrelin receptors (GHSR-1a), triggering GH pulse initiation with high selectivity.
• What the research shows: Individual component trials show sustained IGF-1 elevation with CJC-1295 and selective pulsatile GH release with ipamorelin; mechanistic synergy between GHRH analogs and GH secretagogues is supported by human research on related compound classes.

What CJC-1295 and Ipamorelin Are

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary. The modified form used in most clinical research contains a drug affinity complex (DAC) technology that covalently binds the peptide to serum albumin, extending its half-life from minutes to several days. A related compound, modified GRF 1-29 (sometimes called CJC-1295 without DAC), lacks this modification and has a half-life closer to 30 minutes, producing a more pulsatile pharmacokinetic profile. These are mechanistically distinct formulations, and the distinction matters clinically.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts at the ghrelin receptor (GHSR-1a) rather than the GHRH receptor. It was developed as a highly selective GH secretagogue, meaning it stimulates GH release without the clinically relevant cortisol, prolactin, or ACTH elevation observed with earlier GHS compounds such as GHRP-2 and GHRP-6. As a ghrelin-mimetic, it represents a structurally distinct class from GHRH analogs, which is the pharmacological basis for their combined use.

The Mechanism Rationale for Combining Them

Two receptor systems, one amplified pulse

Pituitary somatotroph cells (the cells that produce and release GH) express both GHRH receptors and ghrelin receptors. These two receptor systems are not redundant. They operate through distinct intracellular signaling cascades that converge on GH release but do so independently. GHRH receptor activation primarily increases cyclic AMP and opens voltage-gated calcium channels; ghrelin receptor activation primarily works through protein kinase C and a separate calcium-dependent pathway. When both pathways are activated simultaneously, the resulting GH pulse is substantially larger than either receptor could generate alone. This synergy was documented in human subjects by Veldhuis and Bowers in the American Journal of Physiology Endocrinology and Metabolism in 2009, who administered simultaneous 3-hour IV infusions of GHRH and GHRP-2 at 1 mcg/kg/h each following a 3-hour saline baseline in 47 men aged 18 to 74, and found that abdominal-visceral fat, IGF-1, and IGFBP-3 together explained 60% of the variability in GHRH-plus-GHRP synergy (p < 0.001), with no adverse events reported — confirming that the two signaling pathways genuinely augment each other rather than simply summing. A 1993 study by Huhn and colleagues in the Journal of Clinical Endocrinology and Metabolism had earlier given 8 healthy young men continuous 24-hour IV GHRP infusions at 1.0 mcg/kg/h on two occasions and found GH secretion rates rose approximately 8-fold versus saline (12 ± 2.1 vs. 1.5 ± 0.34 mcg, p < 0.05) with pulse number, amplitude, and interpeak valley concentrations all elevated and no significant adverse effects, providing the receptor-tachyphylaxis context for sustained use. A more recent 2013 paper by Norman and colleagues in the American Journal of Physiology Regulatory, Integrative and Comparative Physiology — a prospectively randomized, double-blind, placebo-controlled crossover trial in 26 healthy older men (13 testosterone, 13 placebo) using six 16-hour overnight sessions with GHRH (1 mcg/kg), somatostatin (0.67 mcg/kg), GHRP-2 infusion, and L-arginine (30 g IV) — found that testosterone roughly doubled pulsatile GH secretion during GHRH pulses combined with continuous saline (p < 0.01), further characterizing differential pulsatile secretagogue control of GH secretion.

CJC-1295 and pulsatility

The foundational human pharmacology of CJC-1295 (with DAC) was established by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 across two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61 years. A single subcutaneous dose of 1 to 30 mcg/kg produced dose-dependent mean GH elevations of 2- to 10-fold that persisted for 6 or more days, with mean IGF-1 rising 1.5- to 3-fold above baseline; weekly or biweekly dosing extended IGF-1 elevation up to 28 days, and no serious adverse reactions were reported in the Phase 1 trial at the tested doses. A companion analysis by Ionescu and Frohman, also in the Journal of Clinical Endocrinology and Metabolism in 2006, confirmed that pulsatile GH secretion was preserved during this sustained GHRH stimulation: GH continued to be released in discrete pulses rather than continuously, a finding with important clinical implications. Continuous GH elevation tends to produce more insulin resistance and receptor downregulation than pulsatile release. Modified GRF 1-29 (without DAC) has a much shorter half-life and supports a pharmacokinetic profile closer to endogenous pulsatility, making it distinct from the long-acting CJC-1295 with DAC in its GH release pattern.

Ipamorelin and selectivity

Ipamorelin's defining characteristic among GH secretagogues is its selectivity profile. Raun and colleagues, writing in the European Journal of Endocrinology in 1998, demonstrated in a preclinical model that ipamorelin released GH at levels comparable to GHRP-6 but without the cortisol, prolactin, or ACTH release that earlier secretagogues produced. The medicinal chemistry lineage behind ipamorelin is documented in two companion Journal of Medicinal Chemistry papers from 1998 — Hansen and colleagues on novel orally active secretagogues and Ankersen and colleagues on the potent GHRP series derived from ipamorelin. The pharmacokinetic behavior in human volunteers was subsequently modeled by Gobburu and colleagues in Pharmaceutical Research in 1999, confirming a short half-life and dose-proportional GH release consistent with a pulsatile mechanism. A 1999 rat study by Johansen and colleagues in Growth Hormone and IGF Research further demonstrated ipamorelin-induced longitudinal bone growth, providing a preclinical read on GH axis engagement. The selectivity of ipamorelin for the GH axis over the HPA (hypothalamic-pituitary-adrenal) axis is what distinguishes it from structurally related GHRPs and makes it the most commonly studied ghrelin-mimetic in combination research contexts.

The synergy logic in practice

The combination rationale builds directly from the Veldhuis and Bowers synergy data and from three decades of GHRH-plus-GHRP research. Bowers and colleagues published a landmark study in the Journal of Clinical Endocrinology and Metabolism in 1990 in 18 normal adult men using IV bolus GHRP (0.1, 0.3, 1.0 mcg/kg) alone and combined with GHRH (1.0 mcg/kg), where peak GH rose from 1.2 ± 0.3 mcg/L on placebo to 7.6 ± 2.5, 16.5 ± 4.1, and 68.7 ± 15.5 mcg/L at ascending GHRP doses (approximately 6- to 57-fold), with submaximal GHRP plus GHRH producing synergistic responses exceeding the sum of either alone; no adverse clinical effects or laboratory abnormalities were observed and prolactin/cortisol only rose approximately 2-fold at the top dose. This foundational finding has been replicated across multiple compound classes. Bowers and colleagues also demonstrated in a 2004 Journal of Clinical Endocrinology and Metabolism study of older men and women using continuous subcutaneous GHRP-2 infusion at 1 mcg/kg/h for 30 days (n = 17 in the chronic cohort) that GH secretion remained stimulated more than 3-fold on day 1 and more than 1.8-fold on days 14 and 30 (p < 0.001), with IGF-1 elevated to a stable plateau across days 1, 14, and 30 (p < 0.025) and safety screening tests remaining normal — suggesting the pulsatile release mechanism is preserved with sustained GHS exposure without desensitization. Critically, no published human RCTs of the specific CJC-1295-plus-ipamorelin combination exist as of April 2026. The combination rationale is derived from individual component pharmacology and mechanistic synergy studies using related GHRH-plus-GHRP pairings, not from direct head-to-head combination trials.

What the Individual Compound Research Shows

CJC-1295: IGF-1 elevation and axis engagement

Beyond the Teichman 2006 pharmacokinetic data, Sackmann-Sala and colleagues published a 2009 proteomic study in Growth Hormone and IGF Research analyzing serum from 11 healthy men before and one week after a single CJC-1295 injection using 2D gel electrophoresis with mass spectrometry; they identified decreases in apolipoprotein A1 and transthyretin isoforms and increases in beta-hemoglobin, albumin fragments, and immunoglobulin fragments, with the immunoglobulin/albumin fragment spot showing a linear relationship with IGF-1 levels — consistent with downstream GH/IGF-1 axis engagement beyond a transient hormone spike, though the small uncontrolled cohort limits generalization. The DAC technology described by Jetté and colleagues in Endocrinology in 2005 established that the bioconjugation mechanism underlying CJC-1295's prolonged half-life involves covalent binding to endogenous albumin, a pharmacokinetic strategy that substantially changes the compound's clinical behavior relative to shorter-acting GHRH analogs. Importantly, the sustained IGF-1 elevation produced by CJC-1295 with DAC differs from the shorter elevation produced by modified GRF 1-29, and the two should not be treated as interchangeable in any discussion of pharmacodynamic effects.

Ipamorelin: the human efficacy picture

Ipamorelin's clinical development history includes one published Phase 2 human efficacy trial. Beck, Sweeney, and McCarter, writing in the International Journal of Colorectal Disease in 2014, conducted a multicenter, double-blind, placebo-controlled Phase 2 trial (n = 114 modified intent-to-treat) testing intravenous ipamorelin 0.03 mg/kg twice daily for up to 7 days versus placebo in adults undergoing open or laparoscopic bowel resection; ipamorelin was well tolerated but produced no significant difference versus placebo on the key or secondary efficacy endpoints, meaning the trial did not meet its primary endpoint. This is the only published Phase 2b human efficacy trial of ipamorelin as of April 2026, and its failure is a material fact that any honest discussion of the compound's evidence base must include. Preclinical gastroprokinetic data from Venkova, Mann, Nelson, and Greenwood-Van Meerveld in the Journal of Pharmacology and Experimental Therapeutics in 2009 (rodent model of postoperative ileus; ipamorelin 0.01–1 mg/kg IV accelerated time to first bowel movement after single dosing and increased cumulative fecal output, food intake, and body weight gain with repetitive dosing) supported the rodent hypothesis; the human trial did not replicate it. Ipamorelin has not been evaluated in published human trials for body composition, recovery, or anti-aging outcomes. The GH axis effects documented in the preclinical and pharmacokinetic literature have not been translated into published human efficacy data for these applications. The rat longitudinal bone growth data referenced above provides mechanistic context but cannot substitute for human trial data.

Comparator class data: what GHS outcomes research shows

The most directly relevant human outcomes data for the GHS class comes from studies of MK-677 (ibutamoren), an orally active ghrelin receptor agonist structurally distinct from ipamorelin but operating through the same receptor. Nass and colleagues, in a 2-year randomized, placebo-controlled trial published in Annals of Internal Medicine in 2008, gave 65 healthy adults aged 60 to 81 (23 men, 25 women on HRT, 17 women without HRT) oral MK-677 25 mg once daily or placebo, and at 12 months found fat-free mass rose by 1.1 kg (95% CI 0.7 to 1.5) on MK-677 versus -0.5 kg (95% CI -1.1 to 0.2) on placebo (p < 0.001); fasting glucose rose by 5 mg/dL (p = 0.015) with decreased insulin sensitivity, appetite increased transiently before subsiding within months, and mild lower-extremity edema and muscle pain occurred — notably, the lean mass gain did not translate into strength or functional improvement. Chapman and colleagues, in a Journal of Clinical Endocrinology and Metabolism report from 1996, dosed 32 healthy adults aged 64 to 81 (15 women, 17 men) with oral MK-677 at 2, 10, or 25 mg daily or placebo across 14- and 28-day periods and found IGF-1 rose from 141 ± 21 mcg/L at baseline to 219 ± 21 at 2 weeks and 265 ± 29 at 4 weeks on the 25 mg dose (p < 0.05, restoring values to the young-adult reference range), with GH pulse height and interpulse nadir rising without change in pulse number, cortisol unchanged, and prolactin increasing 23% while staying within normal range. Structural biology of the ghrelin receptor itself has been clarified by a 2021 cryo-EM study by Shiimura and colleagues in Nature Communications characterizing the basis of ghrelin receptor signaling by ghrelin and ibutamoren, and a 2021 review by Price, Ley, and Gorvin in the Journal of Endocrinology surveyed heterodimerization and interacting proteins at this receptor. The original 1996 Howard and colleagues cloning paper in Science established GHSR as the pituitary and hypothalamic G protein-coupled receptor that both ghrelin and synthetic GH secretagogues engage. These findings in a related compound class provide the most robust human outcomes framework available for understanding what ghrelin receptor activation achieves biologically, while acknowledging that MK-677 and ipamorelin have distinct structures, pharmacokinetics, and clinical profiles and cannot be directly extrapolated to each other.

CJC-1295 and Ipamorelin Compared to Related Compounds

Understanding where this combination sits within the broader GH-axis pharmacology landscape requires comparing it to three reference points: sermorelin, tesamorelin, and exogenous HGH.

Vs. sermorelin

Sermorelin is a synthetic 29-amino-acid fragment of GHRH with regulatory history in the United States, including FDA approval for pediatric GH deficiency diagnosis (since withdrawn) and subsequent compounding use in adults. Walker's 2006 review in Clinical Interventions in Aging and Prakash and Goa's 1999 pharmacology review in BioDrugs provide context: sermorelin's mechanism is identical in principle to CJC-1295 (GHRH receptor agonism) but with a much shorter half-life and no DAC modification. Sermorelin requires more frequent administration to produce sustained IGF-1 effects. Neither sermorelin nor CJC-1295 targets the ghrelin receptor; sermorelin lacks the complementary GHS activity that ipamorelin provides. As of April 2026, sermorelin occupies a different regulatory position from CJC-1295: sermorelin's compounding status under 503A is distinct and should be verified with a regulatory professional before drawing clinical equivalence.

Vs. tesamorelin

Tesamorelin is the only GHRH analog that is FDA-approved, indicated for HIV-associated lipodystrophy. Falutz and colleagues published the pivotal Phase 3 trial in the New England Journal of Medicine in 2007, and Stanley, Feldpausch, Oh, and colleagues published the visceral adipose tissue data in JAMA in 2014. Tesamorelin's approval is narrow and specific; it is not approved for general anti-aging or body composition use. The existence of FDA-approved tesamorelin does not confer regulatory legitimacy to CJC-1295 for non-approved uses, and the two should not be treated as interchangeable either pharmacologically or regulatorily.

Vs. exogenous HGH

Exogenous recombinant human growth hormone (HGH) bypasses the pituitary entirely, delivering GH directly into circulation. This suppresses the hypothalamic-pituitary feedback loop and produces continuous rather than pulsatile GH exposure. The insulin resistance and acromegalic side effects associated with supraphysiological HGH use are well-documented, as reviewed by Díez, Sangiao-Alvarellos, and Cordido in the International Journal of Molecular Sciences in 2018. The theoretical advantage of secretagogue-based approaches is that they work within the existing feedback architecture: IGF-1 elevation feeds back to reduce GH release, providing a physiological ceiling. Olshansky and Perls addressed the illegal provision of growth hormone for anti-aging and bodybuilding in JAMA in 2008, noting the absence of robust evidence for anti-aging HGH use alongside well-characterized risks. The GH secretagogue approach, in principle, preserves regulatory feedback that exogenous HGH eliminates — though this theoretical advantage has not been tested in controlled head-to-head human trials comparing the two approaches.

Biomarkers to Monitor When Considering This Combination

Because CJC-1295 and ipamorelin both act on the GH/IGF-1 axis, the same set of biomarkers applies whether considering either compound individually or together. The following markers are clinically relevant to understanding GH axis function, monitoring downstream effects, and identifying individuals for whom elevated IGF-1 warrants caution.

• IGF-1 (Insulin-Like Growth Factor 1): The primary downstream marker of sustained GH axis activity. IGF-1 reflects the integrated GH secretion over the preceding hours to days and is the standard monitoring marker in all GH-axis research. Baseline IGF-1 establishes whether the axis is underactive before any intervention. On-therapy IGF-1 tracks whether the axis is responding and whether levels remain within the physiological range. Zhang, Ye, Barzilai, and Milman, writing in Aging Cell in 2021, analyzed UK Biobank data (n = 440,185) and described the antagonistic pleiotropy of IGF-1 — younger individuals with high IGF-1 were protected from disease, while older individuals with high IGF-1 were at increased risk for incident disease or death, with a generally U-shaped risk relationship across most age-associated conditions and a more uniformly positive association with cancer. Qian and Huo in a 2020 UK Biobank cohort study of 412,645 adults published in Cancer Epidemiology, Biomarkers and Prevention, examined circulating IGF-1 and risk across total and 19 site-specific cancers, reinforcing the importance of monitoring IGF-1 rather than assuming higher is better. Establishing this baseline before any GH-axis intervention is a prerequisite for objective interpretation of any observed effects.
• Fasting glucose: GH is a counter-regulatory hormone that opposes insulin action. Elevated GH and IGF-1 can reduce glucose uptake and worsen insulin sensitivity, a well-characterized effect documented in the GHS outcomes literature. Fasting glucose at baseline establishes metabolic risk before any GH-axis modification is considered. Reference ranges vary by lab and individual; your provider will interpret results in context.
• Hemoglobin A1c (HbA1c): Reflects average glucose over the prior 8 to 12 weeks. For anyone considering prolonged GH-axis stimulation, HbA1c provides a longer-term metabolic safety signal that a single fasting glucose cannot. A rising HbA1c during GH-axis intervention would prompt reassessment of dose, timing, or candidacy. Reference ranges vary by lab and individual; your provider will interpret results in context.
• Insulin: Fasting insulin is more sensitive than fasting glucose for detecting early insulin resistance. Because GH receptor-mediated effects on insulin sensitivity can precede changes in fasting glucose, baseline and on-therapy insulin measurements provide earlier signal of any metabolic impact.
• Fasting cortisol: Relevant specifically for differentiating ipamorelin from other GH secretagogues. Ipamorelin's selectivity for the GH axis over the HPA axis is a claimed advantage, but verifying that cortisol remains unperturbed in an individual patient requires measurement. Raun and colleagues' 1998 selectivity data was preclinical; individual human responses can vary.
• Prolactin: Similarly, ipamorelin's reduced propensity to stimulate prolactin compared to GHRP-2 and GHRP-6 is a pharmacological distinction, not a guarantee. A baseline prolactin value, particularly in individuals with any symptoms suggestive of HPA axis involvement, provides interpretive context for any changes observed.

Who Typically Asks About This Combination

The search volume behind "CJC-1295 ipamorelin" primarily reflects interest from adults concerned about age-related changes in body composition, recovery, and energy, who have encountered these compounds in the context of wellness medicine or longevity-oriented practices. The clinical profile most commonly discussed in the research context is adults with documented low IGF-1 relative to age-adjusted reference ranges, combined with symptoms consistent with reduced GH axis activity: declining lean mass, increased visceral fat, prolonged recovery from exercise, and disrupted slow-wave sleep. Van Cauter, Leproult, and Plat's landmark study in JAMA in 2000 pooled polygraphic sleep recordings and 24-hour plasma hormone profiles from 149 healthy men aged 16 to 83 across four laboratories (1985–1999) and found slow-wave sleep fell from 18.9% of sleep time in early adulthood (ages 16–25) to 3.4% by midlife (ages 36–50), with GH secretion declining by approximately 372 mcg per decade from early to midlife (p < 0.001) and a further 43 mcg per decade from midlife to late life (p < 0.02), and a statistically significant correlation between slow-wave sleep amount and GH secretion (p < 0.001) — providing mechanistic context for sleep-related symptom patterns in this population.

The critical caveat is that identifying this clinical profile does not establish an approved therapeutic pathway for CJC-1295 or ipamorelin. As of April 2026, both compounds are on the FDA's 503A Category 2 list, which means licensed 503A compounding pharmacies cannot legally prepare them pending further FDA review. Any provider considering these compounds for a patient must navigate the current regulatory status with the involvement of qualified legal and regulatory counsel.

Who Should Not Pursue GH Axis Stimulation

The following are clinical characteristics that make GH axis stimulation, whether via CJC-1295, ipamorelin, or any related compound, inappropriate or high-risk. This list reflects considerations from the published literature on GH and IGF-1 biology and does not constitute individualized medical advice.

• Active or history of malignancy — GH and IGF-1 have well-characterized mitogenic properties; the Qian and Huo 2020 UK Biobank cohort identified associations between elevated circulating IGF-1 and risk across multiple site-specific cancers.
• Uncontrolled diabetes or significant insulin resistance — GH is a counter-regulatory hormone; adding GH axis stimulation in the context of impaired glucose metabolism creates additive metabolic risk.
• Acromegaly or any condition associated with excess GH or IGF-1 — stimulating a GH axis that is already overactive would compound existing pathology.
• Pregnancy or breastfeeding — safety has not been established in these populations for any GH secretagogue compound.
• Active pituitary pathology — conditions affecting the anterior pituitary (tumors, prior radiation, hypopituitarism of pituitary origin) change the pharmacodynamic response to GHRH-based stimulation in ways that require specialist evaluation.
• Use of other compounds affecting the GH/IGF-1 axis without provider supervision — pharmacological interactions involving GH axis modulators require clinical oversight, particularly regarding glucose metabolism and receptor sensitivity.

A qualified healthcare provider will conduct a full evaluation before any clinical decision involving GH-axis-active compounds. This list is not exhaustive.

Side Effects Reported in the Component Research

Because no published human RCTs of the CJC-1295-plus-ipamorelin combination exist, the side effect data below reflects the individual compound literature. Combined use may produce different or additive effects not captured in individual compound studies.

Reported with CJC-1295 (Teichman 2006 and related):

• Injection site reactions (redness, swelling, pain at the subcutaneous injection site — the most commonly reported adverse event in the Teichman trial)
• Transient flushing and headache (reported in the acute post-injection period)
• Water retention or peripheral edema (a recognized GH class effect associated with sodium retention)
• Potential for IGF-1 elevation above the age-adjusted reference range at higher doses (requires monitoring)

Reported with ipamorelin (Raun 1998, Gobburu 1999, Beck 2014):

• Injection site discomfort
• Transient flushing and headache in the acute post-injection window
• Increased appetite (a ghrelin-receptor class effect; Wren and colleagues in a 2001 randomized, double-blind, crossover trial in the Journal of Clinical Endocrinology and Metabolism, infused IV ghrelin at 5.0 pmol/kg/min versus saline in 9 healthy volunteers and found every subject increased free-choice buffet intake, with a mean 28 ± 3.9% rise in energy consumed on ghrelin (p < 0.001) and higher visual appetite scores, establishing ghrelin as the first circulating hormone shown to stimulate human food intake — relevant context for any ghrelin-mimetic)
• The selectivity data from Raun 1998 suggests a lower cortisol and prolactin signal than GHRP-2 or GHRP-6, but individual variation exists and monitoring is appropriate

Is This Combination Legal?

As of April 2026, both CJC-1295 and ipamorelin appear on the FDA's 503A Category 2 bulk substances list. Category 2 designation means the FDA has identified these substances as presenting potential safety risks or lacking sufficient evidence to support compounding, and they cannot be legally compounded under Section 503A while the agency's review is ongoing. A 2024 statement by the Obesity Medicine Association, published in Obesity Pillars, addressed the compounded peptide regulatory landscape and is a useful reference for anyone navigating the current regulatory environment.

With that regulatory context established, neither compound is FDA-approved for any indication. Neither has completed a full Phase 3 clinical development program for any therapeutic use. As of April 2026, access to these compounds through a 503A compounding pharmacy is not a legally available pathway. Any individual or provider considering these compounds must engage qualified regulatory and legal counsel regarding current applicable law.

The WADA (World Anti-Doping Agency) dimension is also relevant. Memdouh, Gavrilović, Ng, Cowan, and Abbate published a 2021 review of advances in detection of synthetic GHRH analogs including CJC-1295 in Drug Testing and Analysis, confirming that GHRH analogs are detectable in sport testing. As of the 2026 WADA Prohibited List, all growth hormone-releasing factors — including GHRH analogs and GH secretagogues — are classified as prohibited substances in competition under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). This prohibition applies to CJC-1295 and ipamorelin specifically.

Understanding Your Baseline Before Engaging With GH-Axis Research

The most important thing a person can do before considering any intervention that acts on the GH/IGF-1 axis is establish a precise, dated baseline for the biomarkers that axis controls. IGF-1 is the critical starting point: its value relative to the age-adjusted reference range is the primary determinant of whether GH axis activity is genuinely suboptimal or within expected parameters. Fasting glucose and HbA1c establish metabolic context. Without these baselines, any perceived effect from a GH-axis-active compound cannot be distinguished from normal biological variation, seasonal fluctuation, or placebo response. With them, changes become measurable and interpretable.

That principle — establish the baseline, then evaluate change against it — is central to Superpower's approach to preventive health. Whatever direction a person's health investigation takes, the data should come first. Understanding your IGF-1 trajectory, and the metabolic markers that contextualize it, is a concrete first step that belongs before any pharmacological decision.

IMPORTANT SAFETY INFORMATION

CJC-1295 and ipamorelin are NOT FDA-approved for any indication. As of April 2026, both substances are on the FDA 503A Category 2 bulk substances list and cannot be legally compounded under Section 503A pending further FDA review. Superpower Health does not prescribe, sell, compound, or facilitate access to CJC-1295 or ipamorelin. This page is provided for educational and informational purposes only and does not constitute medical advice, a treatment recommendation, or a clinical protocol.

No completed human RCTs of the CJC-1295-plus-ipamorelin combination have been published as of April 2026. Evidence for individual component pharmacology in humans exists but does not establish safety or efficacy for any specific clinical indication. Long-term safety data for either compound in humans is not available.

Contraindications (based on GH-axis compound class data and published component research): active or history of malignancy; uncontrolled diabetes or significant insulin resistance; acromegaly or conditions associated with excess GH/IGF-1; pregnancy or breastfeeding; active pituitary pathology; known hypersensitivity to the compound or its excipients.

Warnings: elevated IGF-1 above age-adjusted reference range (monitor); insulin resistance and glucose intolerance (GH class effect; monitor fasting glucose and HbA1c); water retention and edema (GH class effect); increased appetite (ghrelin receptor class effect); injection site reactions.

Common side effects from individual compound trials: injection site redness and swelling; transient flushing and headache; water retention; increased appetite.

Sport ban status: As of the 2026 WADA Prohibited List, CJC-1295 and ipamorelin are prohibited in competition under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Any athlete subject to anti-doping rules must consult the current WADA Prohibited List and their sport's governing body before engaging with any GH secretagogue or GHRH analog.

Compound reference data: PubChem CID 20515892 (ipamorelin); PubChem CID 56841945 (CJC-1295).

Additional Questions

How does ipamorelin differ from GHRP-2 and GHRP-6?

Ipamorelin, GHRP-2, and GHRP-6 are all synthetic GH secretagogues that activate the ghrelin receptor, but their selectivity profiles differ substantially. Raun and colleagues demonstrated in 1998 that ipamorelin releases GH without the cortisol, prolactin, and ACTH elevation observed with GHRP-2 and GHRP-6. This selectivity for the GH axis relative to the HPA axis is ipamorelin's defining pharmacological characteristic and the reason it became the preferred GHS in combination research contexts. GHRP-2 and GHRP-6 are Category 3 substances under current FDA classification and cannot be compounded.

Does sermorelin work the same way as CJC-1295?

Both sermorelin and CJC-1295 act as GHRH receptor agonists, but their pharmacokinetics differ significantly. Sermorelin is a 29-amino-acid fragment of GHRH with a short half-life requiring more frequent administration. CJC-1295 with DAC uses albumin binding to extend its half-life to several days, producing sustained IGF-1 elevation from infrequent dosing. The result is different GH release profiles: sermorelin produces a pharmacokinetic pattern closer to pulsatile endogenous GHRH, while CJC-1295 with DAC produces prolonged, sustained GH axis stimulation. They are not clinically equivalent, and their current regulatory statuses differ as of April 2026.